Pharma was launched in 2008 by Optometry Australia to support the emergence of therapeutics in optometry. It is distributed free-of-charge to all Optometry Australia members and members of the New Zealand Association of Optometrists (NZAO).
Pharma is published quarterly (March, June, September and December) and offers Australian members six accredited clinical CPD points per issue. It features quality editorial with a strong emphasis on stories that promote cutting-edge therapeutic developments and research as well as clinical case studies.
It is an objective of Pharma to provide information that optometrists can use immediately in their day-to-day patient care or that will assist them to improve their knowledge across a range of eye health issues.
Submit your case report to Pharma magazine
Pharma provides members of Optometry Australia and the New Zealand Association of Optometrists the opportunity to submit a case report for consideration for publication.
For your case report to be considered, send a 200-word explanatory summary, plus 1-2 captioned images, scans or graphs to email@example.com. Terms and conditions apply. (See below).
CPD points for your contribution
Australian optometrists who create optometric editorial content that is published in Pharma can claim 1 (one) CPD point per hour spent researching and writing under the ‘independent learning – clinical’ category. See the Optometry Board of Australia’s ‘Guidelines for continuing professional development for endorsed and non-endorsed optometrists’ for more information.
New Zealand optometrists can claim CPD credits for case reports by submitting an application to NZAO for the CPD recording program manager.
Terms and conditions
1.0 Case report contributions
1.1 To be considered to contribute a case report, you need to:
(1) Be a current member of Optometry Australia (including student members) or the New Zealand Association of Optometrists.
(2) Submit an explanatory summary (maximum 200 words in total) of your case report that highlights:
- The eye health presentation
- The treatment regime
- Key learnings
(3) Submit a short summary of any graphs, diagrams, charts and/or images that you have to support your case report (you can attach 1-2 images)
(4) Ensure that you include your full name, practice or employer name, contact details and membership number on your submission
(5) Send your submission to: firstname.lastname@example.org
1.2 Pharma’s Editor and Clinical Editor will review all case report submissions and their decision will be final on the case reports that will be accepted to be published in Pharma.
1.3 In the event that your submission is successful you will be required to write an original piece of editorial, featuring your case report, for publication in Pharma.
The Editor will inform you how many words your case report should be, how many graphs, diagrams, charts and/or images (‘figures’) will be required and the deadline for your case report to be submitted. You may decline the offer to submit your case report but if the offer is accepted, there will be the expectation that you will deliver on your commitment.
(1) The Editor and Clinical Editor reserve the right to:
- Ask you to revise or rewrite all, or part of, your case report if they feel it does not meet Pharma’s editorial standards.
- Edit your case report
- Decide not to publish your case report.
- Reject work that is considered not original.
1.4 You will not receive a fee, or any form of compensation, for your case report contribution.
1.5 You have the right to withdraw a case report from being published within 10 working days of the date that you submitted it to Optometry Australia.
2.1 Optometry Australia will not publish any case report where the patient has been clearly identified unless that patient has provided, in writing, permission for their identity to be included. In such a case, you must provide Optometry Australia with a copy of this written permission.
3.0 Intellectual property
3.1 You will be credited as the author of the case report.
3.2 Once your original piece of editorial has been accepted for publication by Optometry Australia, ownership of the copyright will transfer to Optometry Australia.
(1) Optometry Australia will consider applications from authors who wish to submit their case report to other publications. Copyright laws require such applications to be made in writing. Applications will not be considered when:
- Optometry Australia has accepted and approved a case report but that case report has not yet been published in Pharma.
- The case report has been published in Pharma in the past 12 months.
3.3 When you submit figures for publication with your case report:
(1) You grant Optometry Australia a perpetual global rights license to publish these graphics with your case report in all Pharma distribution channels owned by Optometry Australia and NZAO.
(2) Where ownership in the graphics resides with another party, you must seek written permission from them and obtain a perpetual global rights license for Optometry Australia to publish their graphics with your case report in all Pharma distribution channels owned by Optometry Australia and NZAO.
3.4 Where these IP conditions cannot be met, Optometry Australia will be unable to publish your case report.